newdrugapprovals.org
Luseogliflozin, TS 071…………. strongly inhibited SGLT2 activity,
LUSEOGLIFLOZIN, CAS 898537-18-3 An antidiabetic agent that inhibits sodium-dependent glucose cotransporter 2 (SGLT2). (1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-gluci…